When was Ypsomed founded?

Ypsomed was founded in 2003 and raised its 1st funding round within a year of its incorporation.

Where is Ypsomed located?

Ypsomed is headquartered in Burgdorf, Switzerland. It is registered at 10/61/1-F KIRTI NAGAR INDUSTRIAL AREA, NEW DELHI, Delhi, India, 110015.

Who is the current CEO of Ypsomed?

Simon Michel of Ypsomed. They are also an angel investors in 1 startup.

How many employees does Ypsomed have?

As of Apr 30, 2026, the latest employee count at Ypsomed is 1373.

Is Ypsomed a funded company?

Ypsomed is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on 2003.

When was the latest funding round of Ypsomed?

Ypsomed's latest funding was a $***** Series A round on 2003, with participation from 1 investor.

What is the annual revenue of Ypsomed?

Annual revenue of Ypsomed is £23.5M as on Mar 31, 2025.

Where does Ypsomed rank among its competitors?

Ypsomed ranks 5th amongst 58 active competitors, of which 11 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Kaleido, which secured $13M in Jan, 2026.

Who are the top competitors of Ypsomed?

Ypsomed's top competitors include Tandem Diabetes, Insulet and Kaleido. Among them, Kaleido secured the most recent funding round in January, 2026.

Ypsomed - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of self delivery injection systems and diabetes care systems. The company develops and manufactures injection systems for self-medication and supplier of products for diabetes care. The product portfolio includes Blood Glucose Monitoring Systems, Pen and safety pen needles, Infusion systems,

Website: www.ypsomed.com/en/
Email ID: *****@ypsomed.com
Phone Number: +41 **********
Registered Address: 10/61/1-F KIRTI NAGAR INDUSTRIAL AREA, NEW DELHI, Delhi, India, 110015

Key Metrics

Founded Year

2003

Location

Burgdorf, Switzerland

Stage

Acquired

Total Funding

$7.45M in 1 round

Latest Funding Round

Series A, 2003, $*****

Investors

BV Partners & 1 more

Ranked

5^th among 58 active competitors

Annual Revenue

£23.5M as on Mar 31, 2025

Employee Count

1,373 as on Apr 30, 2026

Investment & Acquisitions

CeQur

Similar Companies

Insulet & 36 more

Exit Details

Acquired by TecMed Deutschland (Apr 24, 2025)

View Ypsomed's full profile

Ypsomed is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count
YPSOMED INDIA PRIVATE LIMITED CIN: U74120DL2007PTC170003 , India, Active	Oct 31, 2007	$1.83M (As on Mar 31, 2025)	-
Ypsomed ApS CIN: 39888041 , Denmark, Active	Sep 23, 2018	-	-
YPSOMED LIMITED CIN: 7132723 , United Kingdom, Active	Jan 20, 2010	$30M (As on Mar 31, 2025)	39 (As on Mar 31, 2025)

Ypsomed got acquired by TecMed Deutschland on Apr 24, 2025.

Click here to take a look at Ypsomed's acquisition in detail

Ypsomed has raised a total funding of $7.45M over 1 round. Its latest funding round was a Series A round on 2003 for $*****. 1 investor participated in its latest round. Ypsomed has 2 institutional investors.

Here is the list of recent funding rounds of Ypsomed:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
2003	9816	Series A	3993	7082	9378	1871

Access funding benchmarks and valuations. Sign up today!

View details of Ypsomed's funding rounds and investors

Ypsomed's employee count trend

Ypsomed has 1,373 employees as of Apr 26. Here is Ypsomed's employee count trend over the years:

Uncover Ypsomed's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Ypsomed include Tandem Diabetes, Insulet and Kaleido. Here is the list of Top 10 competitors of Ypsomed, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Tandem Diabetes 2008, San Diego (United States), Public	Developer of devices for continuous glucose monitoring and manual insulin delivery	$101M	Gynther Capital, Domain Associates & 5 others	78/100
2nd	Insulet 2000, Boston (United States), Public	Manufacturer of wearable, tubeless insulin delivery systems for diabetes management	$120M	Federated Hermes, Piper Jaffray & 13 others	78/100
3rd	Kaleido 2013, Utrecht (Netherlands), Series D	Developer of insulin therapy for treating diabetes	$183M	Life Sciences Partners, Inkef & 10 others	63/100
4th	Sigrid Therapeutics 2014, Stockholm (Sweden), Series C	Developer of therapies to treat metabolic and chronic lifestyle diseases	$27M	Irrus Investments, Joyance Partners & 9 others	61/100
5th	Ypsomed 2003, Burgdorf (Switzerland), Acquired	Developer of self delivery injection systems and diabetes care systems	$7.45M	BV Partners, BV Group	62/100
6th	Modular Medical 2017, San Diego (United States), Series A	Developer of insulin pump for insulin delivery	$5.28M	-	56/100
7th	Embecta 2022, Parsippany (United States), Public	Manufacturer of insulin delivery solutions, including pen needles and insulin syringes	-	-	56/100
8th	Microtech Medical 2011, Hangzhou (China), Public	Medical devices developer for diabetes care	$88.2M	IDG Capital, Tencent & 9 others	56/100
9th	Valeritas 2003, Bridgewater (United States), Acquired	Developer of wearable insulin patch pumps for insulin delivery through the skin	$231M	Welsh, Carson, Anderson & Stowe, Abingworth ... & 12 others	53/100
10th	Omnipod 1999, Acton (United States), Unfunded	Provider of smart wearable disposable pod provides insulin delivery	-	-	53/100